Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/213982
Title: | Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients |
Author: | Rodríguez Espinosa, Diana Montagud Marrahi, Enrique Cacho, Judit Arana, Carolt Taurizano, Natalia Hermida, Evelyn Del Risco Zevallos, Jimena Casals Urquiza, Joaquim Rosario, Anney Cuadrado Payán, Elena Molina Andújar, Alícia Rodríguez, Néstor Vilella i Morató, Anna Bodro, Marta Ventura Aguiar, Pedro Revuelta, Ignacio Cofán Pujol, Federico Poch, Esteban Oppenheimer Salinas, Federico Vera, Manel Rodas, Lida M. Cases, Aleix Bayés, Beatriu Diekmann, Fritz Maduell, Francisco Broseta, José Jesús Cucchiari, David |
Keywords: | COVID-19 Trasplantament renal Hemodiàlisi Vacunació SARS-CoV-2 COVID-19 Kidney transplantation Hemodialysis Vaccination SARS-CoV-2 |
Issue Date: | 21-Feb-2022 |
Publisher: | Springer Verlag |
Abstract: | Introduction: Given the increased COVID-19 observed in kidney transplant recipients (KTRs) and haemodialysis patients, several studies have tried to establish the efficacy of mRNA vaccines in these populations by evaluating their humoral and cellular responses. However, there is currently no information on clinical protection (deaths and hospitalizations), a gap that this study aims to fill. Methods: Observational prospective study involving 1,336 KTRs and haemodialysis patients from three dialysis units affiliated to Hospital Clínic of Barcelona, Spain, vaccinated with two doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 mRNA vaccines. The outcomes measured were SARS-CoV-2 infection diagnosed by a positive RT-PCR fourteen days after the second vaccine dose, hospital admissions derived from infection, and a severe COVID-19 composite outcome, defined as either ICU admission, invasive and non-invasive mechanical ventilation, or death. Results: Six per cent (18/302) of patients on haemodialysis were infected, of whom four required hospital admission (1.3%), only one (0.3%) had severe COVID-19, and none of them died. In contrast, 4.3% (44/1034) of KTRs were infected, and presented more hospital admissions (26 patients, 2.5%), severe COVID-19 (11 patients, 1.1%) or death (4 patients, 0.4%). KTRs had a significantly higher risk of hospital admission than HD patients, and this risk increased with age and male sex (HR 3.37 and 4.74, respectively). Conclusions: The study highlights the need for booster doses in KTRs. In contrast, the haemodialysis population appears to have an adequate clinical response to vaccination, at least up to four months from its administration. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1007/s40620-022-01257-5 |
It is part of: | Journal of Nephrology, 2022, vol. 35, num.3, p. 769-778 |
URI: | http://hdl.handle.net/2445/213982 |
Related resource: | https://doi.org/10.1007/s40620-022-01257-5 |
ISSN: | 1121-8428 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
249002.pdf | 1.75 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.